Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001998191 | SCV002260436 | uncertain significance | Bethlem myopathy 1A | 2023-05-11 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with alanine, which is neutral and non-polar, at codon 520 of the COL6A3 protein (p.Gly520Ala). This variant is present in population databases (rs770496206, gnomAD 0.003%). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt COL6A3 protein function. ClinVar contains an entry for this variant (Variation ID: 1476699). This variant has not been reported in the literature in individuals affected with COL6A3-related conditions. |
Ambry Genetics | RCV002573453 | SCV003709253 | uncertain significance | Inborn genetic diseases | 2021-12-07 | criteria provided, single submitter | clinical testing | The c.1559G>C (p.G520A) alteration is located in exon 5 (coding exon 4) of the COL6A3 gene. This alteration results from a G to C substitution at nucleotide position 1559, causing the glycine (G) at amino acid position 520 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Ce |
RCV003434377 | SCV004147350 | uncertain significance | not provided | 2022-11-01 | criteria provided, single submitter | clinical testing | COL6A3: PM2, BP4 |